Non-peptide

Dasatinib

Also known as

Sprycel · BMS-354825 · Phyrago (dasatinib tablets brand discussed in PK notes) · D+Q (with quercetin) · DQ / D&Q senolytic pair · Dasatinib + quercetin senolytic pair · Intermittent dasatinib (senolytic pulse talk)

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

Identity	A prescription oral leukemia drug, also called Sprycel; a small molecule rather than a peptide.
D+Q interest	Dasatinib plus quercetin is an experimental senolytic pair, discussed for removing cells that stop dividing and can release inflammatory signals. Anti-aging benefit is unproven.

Notes

A prescription oral kinase inhibitor. Dasatinib, including the brand Sprycel, blocks enzymes involved in cell signaling and treats certain leukemias. It is a small-molecule drug, not a peptide. SPRYCEL U.S. Prescribing Information, revised September 2026 (Official context · Accessed 2026-09-30)

Dasatinib is a prescription leukemia drug discussed with quercetin as the experimental senolytic pair D+Q. People hope for less inflammation and better recovery; reports include improvement, no noticeable change and difficult side effects. Anti-aging benefit is unproven.

D+Q means dasatinib plus quercetin. Biohackers discuss this pair as a senolytic: an attempt to remove persistent senescent cells, which stop dividing and can release inflammatory signals. Reddit's mechanism discussion repeats laboratory findings that the two agents affect different cell types; this does not establish whole-body rejuvenation. Reddit r/longevity: How do quercetin and dasatinib interact? (Secondhand community claim · Accessed 2026-09-30)

Short exposure, hoped-for longer change. The 'hit-and-run' idea is to remove cells during brief exposure and spend weeks off the drug. That is the rationale behind community pulses, rather than a daily energy supplement. LongeCity: Senolytic treatment and human senescent-cell burden (Secondhand community claim · Accessed 2026-09-30)

Source context — SPRYCEL U.S. Prescribing Information, revised September 2026: Approved leukemia use/clinical pharmacology; risk frequencies are not healthy intermittent-user estimates.

Source context — Reddit r/longevity: How do quercetin and dasatinib interact?: Research repetition, not human effectiveness or a self-experiment. Relative timestamps were not converted to invented publication dates.

Source context — LongeCity: Senolytic treatment and human senescent-cell burden: Advocacy commentary quoting formal studies; no personal clearance measurements. Original DKD paper was blocked in this session; this is honestly secondary access.

What people notice

Movement and recovery	One rapamycin/D+Q user credits the combination with returning to trail running after arthritis; another notices no effect after over two years of intermittent D+Q.
Energy and sleep	Some describe better vitality, sleep or later recovery. These experiences cannot show that senescent cells were cleared.

Notes

Less pain, better movement and recovery. Todd credits a rapamycin/D+Q combination with a return to trail running after disabling arthritis over two years. George reports no noticeable effect after more than two years of intermittent D+Q. These accounts cannot identify a dasatinib-only benefit. Rapamycin.news: D+Q experiences, George and Todd (Personal report · Accessed 2026-09-30)

Energy and sleep can feel better—or unchanged. Cypherpunk describes vitality and better sleep after dosing while also using rapamycin. Other reports describe later energy/recovery. These impressions cannot prove cell clearance or longer life. Rapamycin.news: Dasatinib Revisit (Community discussion · Accessed 2026-09-30)

Source context — Rapamycin.news: D+Q experiences, George and Todd: Two self-reports, unverified products; Todd used rapamycin throughout and added other agents later. Neither isolates D+Q.

Source context — Rapamycin.news: Dasatinib Revisit: Community discussion includes secondhand prescriber opinions, conflicting tolerance and rapamycin-confounded vitality. Fisetin-only grams in #3/#9 are not dasatinib amounts.

Doses people talk about

100 mg D + 1200 mg Q	One oral account uses these amounts on each of two consecutive days.
100 mg D + 1500 mg Q	Another account uses this oral pair daily within three-day blocks. The 1500 mg is quercetin, not dasatinib.
Other experiments	A separate user reports 100 mg D with 2000 mg Q, sometimes 150 mg D. Another uses 100 mg D with 1000 mg Q, later 1600 mg Q plus 400 mg fisetin.
Forms differ	Community charts also list 100 mg D with about 1000–1500 mg Q daily for 2–3 days. Quercetin powders and enhanced-absorption products are not equivalent by milligrams alone.

Notes

Reported oral pairs: 100 mg D + 1200 mg Q; 100 mg D + 1500 mg Q. Todd reports those first amounts on each of two consecutive days; George reports the second pair daily during three-day blocks. The components and per-day totals matter: 1500 mg is 1.5 g of quercetin, not dasatinib. Rapamycin.news: D+Q experiences, George and Todd (Personal report · Accessed 2026-09-30)

Other reports use different amounts and partners. Cypherpunk reports 100 mg D with 2000 mg Q, sometimes 150 mg D. Another log uses 100 mg D with 1000 mg Q, then 1600 mg Q plus 400 mg fisetin. These are separate experiments. Rapamycin.news: Dasatinib Revisit (Community discussion · Accessed 2026-09-30) · Rapamycin.news: Dasatinib Side Effects (Personal report · Accessed 2026-09-30)

Forms and copied numbers are not interchangeable. Community charts discuss 100 mg D with roughly 1000–1500 mg Q daily for 2–3 days. Fisetin additions or substitutions and quercetin powders versus enhanced-absorption products change the experiment; matching milligrams does not establish equivalence.

Source context — Rapamycin.news: D+Q experiences, George and Todd: Two self-reports, unverified products; Todd used rapamycin throughout and added other agents later. Neither isolates D+Q.

Source context — Rapamycin.news: Dasatinib Side Effects: Unverified self-reports; variable co-agents. Delayed nausea is temporal association, not established drug persistence.

Half-life, onset & duration

Felt onset	No dependable benefit clock: reports mention days or weeks later. Nausea/headache may start within hours; one person reports shaking chills at 12–15 hours.
Felt duration	Benefit duration is unknown. One headache cleared overnight; other accounts report nausea or fatigue days later. Those symptoms do not measure how long the drug remains active.
Half-life	The Sprycel label gives a mean terminal half-life of 3–5 hours. A forum's roughly four-hour figure is research-derived, not a measured rejuvenation window.
Blood peak	The label gives 0.5–6 hours after oral dosing; this is separate from when a benefit might be noticed.

Notes

Unwanted effects can start within hours. KarlT describes nausea/headache within hours and rigors—strong shaking chills—12–15 hours after one dose. Another poster notices head fullness by evening after morning dosing. Feeling ill is not evidence that senescent cells are being cleared. Rapamycin.news: Dasatinib Side Effects (Personal report · Accessed 2026-09-30)

Benefit has no dependable start time. The vitality account describes days after dosing; other reports describe energy/recovery weeks later. Others notice nothing. The 1–2-week 'clearance' narrative borrows study follow-up timing, not measured benefit onset. Rapamycin.news: Dasatinib Revisit (Community discussion · Accessed 2026-09-30) · LongeCity: Senolytic treatment and human senescent-cell burden (Secondhand community claim · Accessed 2026-09-30)

A headache may clear overnight; other symptoms are reported later. Bataille describes a first-night headache gone by morning and little sensation on day two. Basil_Dev reports nausea six days later and fatigue/stomach unease four days after a later pulse. These timings do not show that dasatinib remains active for days. Rapamycin.news: Dasatinib Side Effects (Personal report · Accessed 2026-09-30)

The benefit window remains unknown. Accounts emphasize long drug-free weeks and reassessment across months. LongeCity's 11-day claim refers to biopsy findings after a small kidney-disease study, not 11 days of energy or guaranteed protection until the next pulse. LongeCity: Senolytic treatment and human senescent-cell burden (Secondhand community claim · Accessed 2026-09-30)

The circulated four-hour figure comes from research. LongeCity quotes a paper giving approximately 4 hours for D and 11 hours for Q. Those are research-derived elimination figures repeated in a forum, not community measurements. Half-life means the time for drug concentration to fall by half; it does not time a rejuvenation effect. LongeCity: Senolytic treatment and human senescent-cell burden (Secondhand community claim · Accessed 2026-09-30)

Clinical clearance is measured in hours. The Sprycel label gives a mean terminal half-life of 3–5 hours and peak blood concentrations at 0.5–6 hours after oral dosing. Neither establishes benefit onset or duration. SPRYCEL U.S. Prescribing Information, revised September 2026 (Official context · Accessed 2026-09-30)

Source context — Rapamycin.news: Dasatinib Side Effects: Unverified self-reports; variable co-agents. Delayed nausea is temporal association, not established drug persistence.

Source context — SPRYCEL U.S. Prescribing Information, revised September 2026: Approved leukemia use/clinical pharmacology; risk frequencies are not healthy intermittent-user estimates.

Cycles people discuss

Two-day versus three-day patterns	One user reports two consecutive days every other month. Another uses three consecutive days weekly for three weeks, repeated every 4–5 months.
Other pulses	Single-dose quarterly use, monthly 2–3-day blocks and 11–28-day breaks also appear. No healthy-user schedule is validated by these logs.

Notes

Two days every other month versus repeated three-day clusters. Todd reports two consecutive days every other month. George reports three consecutive days each week for three weeks, repeating every 4–5 months. Cypherpunk's single-dose quarterly pattern is different again. No healthy-user cadence is validated by these logs. Rapamycin.news: D+Q experiences, George and Todd (Personal report · Accessed 2026-09-30) · Rapamycin.news: Dasatinib Revisit (Community discussion · Accessed 2026-09-30)

Weekly, monthly and longer breaks also appear. Community calendars include 11–28-day off periods, monthly 2–3-day blocks, every-other-month use and quarterly clusters. A Reddit commenter describes monthly use for two years without a defined benefit; a proposed 100 mg schedule in the replies is a plan, not an outcome. Reddit r/Biohackers: inexpensive dasatinib and anti-aging (Community discussion · Accessed 2026-09-30)

Source context — Rapamycin.news: D+Q experiences, George and Todd: Two self-reports, unverified products; Todd used rapamycin throughout and added other agents later. Neither isolates D+Q.

Source context — Reddit r/Biohackers: inexpensive dasatinib and anti-aging: Visible nested replies only; claimed 'works great' lacks a defined benefit. Dose-escalation safety assurance rejected; no completed outcome for OP's proposed schedule.

Stacks

Quercetin and fisetin	Quercetin is the core partner in this discussion. Some add fisetin; the reports do not establish a standardized triple or equivalent substitutes.
Other longevity additions	Rapamycin appears in positive logs; charts also list metformin, NMN/NR and spermidine. One user added taurine and GlyNAC after improvement, so they cannot explain its start.

Notes

D+Q (core): Dasatinib + quercetin — the default human senolytic pair in pilots and forums; almost never “D alone” for aging talk. [trial]

D+Q+F: Some add fisetin (another flavonoid senolytic) in self-protocols or sequential glioma/aging trial concepts — not a single standardized triple. [community]

Stack stories make attribution difficult. The positive log added taurine and GlyNAC after improvement; rapamycin was present from the start. Stack charts also include metformin, NMN/NR, spermidine, exercise and sleep. D+Q+fisetin and fisetin-only comparisons do not establish synergy or equivalent alternatives. Rapamycin.news: D+Q experiences, George and Todd (Personal report · Accessed 2026-09-30)

Near rapamycin / sirolimus: Common longevity-stack neighbor (senomorphic vs senolytic framing); concurrent use confounds attribution and raises interaction vigilance (sirolimus is a CYP3A/narrow-therapeutic-range example called out in trial exclusions). [community]

Metformin / NMN–NR / spermidine / exercise / sleep / protein: Listed beside D+Q in “stack charts,” not as proven synergy. [community]

Source context — Rapamycin.news: D+Q experiences, George and Todd: Two self-reports, unverified products; Todd used rapamycin throughout and added other agents later. Neither isolates D+Q.

Watch for

Prescription-drug risks	Label warnings include low blood-cell counts, bleeding, fluid around the lungs, pulmonary hypertension, rhythm problems and fetal harm. Brief use does not establish safety.
Exposure-changing interactions	CYP3A4 inhibitors/inducers and acid-reducing medicines can alter dasatinib levels. Concurrent rapamycin makes the experience harder to assess.
Difficult reactions	Reports include vomiting, fatigue, swollen hands and diarrhea severe enough to stop. Others report no side effects.
Animal warning	A March 2026 mouse paper found myelin damage with D+Q. This is an animal finding, not proof of human brain damage or a safe age threshold.

Notes

Brief courses still involve a potent prescription drug. Label warnings include low blood-cell counts, bleeding, fluid around the lungs, pulmonary hypertension, rhythm problems and fetal harm; clinical monitoring matters. Oncology frequencies cannot estimate intermittent-user risk. Brief exposure does not establish safety. SPRYCEL U.S. Prescribing Information, revised September 2026 (Official context · Accessed 2026-09-30)

Medication interactions can substantially change exposure. CYP3A4 inhibitors or inducers and acid-reducing medicines alter dasatinib levels. Rapamycin stacks complicate assessment. The label separates antacids by at least two hours and avoids PPIs/H2 blockers; that context is not a workaround for self-prescribing. SPRYCEL U.S. Prescribing Information, revised September 2026 (Official context · Accessed 2026-09-30)

Tolerance differs sharply. One three-day user reports no sides at 100 mg; another describes vomiting, neck stiffness, fatigue and swollen hands. Rapamycin.news: Dasatinib Revisit (Community discussion · Accessed 2026-09-30)

Some abandon the experiment. A later Revisit poster stopped because diarrhea was intolerable. Rapamycin.news: Dasatinib Revisit, later replies (Community discussion · Accessed 2026-09-30)

A new mouse warning deserves its actual scope. A March 2026 PNAS paper found myelin damage in young and aged mice given D+Q. It is an animal warning, not proof of human brain damage or an established safe age threshold. Lombardo et al.: oligodendrocyte dysfunction and demyelination (Animal context · Accessed 2026-09-30)

Source context — SPRYCEL U.S. Prescribing Information, revised September 2026: Approved leukemia use/clinical pharmacology; risk frequencies are not healthy intermittent-user estimates.

Source context — Rapamycin.news: Dasatinib Revisit, later replies: The poster's diarrhea experience is first-person; copied warnings and mouse-study news are secondhand. His assertion diarrhea is uncommon is not adopted.

Source context — Lombardo et al.: oligodendrocyte dysfunction and demyelination: Primary paper through a forum-hosted mirror. Mice and rat-cell cultures, not human harms, human frequency or human dose conversions.

Full notes

What Dasatinib is

A prescription oral kinase inhibitor. Dasatinib, including the brand Sprycel, blocks enzymes involved in cell signaling and treats certain leukemias. It is a small-molecule drug, not a peptide. Official context
D+Q means dasatinib plus quercetin. Biohackers discuss this pair as a senolytic: an attempt to remove persistent senescent cells, which stop dividing and can release inflammatory signals. Reddit's mechanism discussion repeats laboratory findings that the two agents affect different cell types; this does not establish whole-body rejuvenation. Reddit r/longevity
Short exposure, hoped-for longer change. The 'hit-and-run' idea is to remove cells during brief exposure and spend weeks off the drug. That is the rationale behind community pulses, rather than a daily energy supplement. LongeCity Community

What people hope to gain

Less pain, better movement and recovery. Todd credits a rapamycin/D+Q combination with a return to trail running after disabling arthritis over two years. George reports no noticeable effect after more than two years of intermittent D+Q. These accounts cannot identify a dasatinib-only benefit. Personal report
Energy and sleep can feel better—or unchanged. Cypherpunk describes vitality and better sleep after dosing while also using rapamycin. Other reports describe later energy/recovery. These impressions cannot prove cell clearance or longer life. Rapamycin.news Community

Doses people discuss

Reported amounts only, not a personal regimen or an approved aging dose. D means dasatinib; Q means quercetin. These reports describe oral tablets with oral co-agents.

Reported oral pairs: 100 mg D + 1200 mg Q; 100 mg D + 1500 mg Q. Todd reports those first amounts on each of two consecutive days; George reports the second pair daily during three-day blocks. The components and per-day totals matter: 1500 mg is 1.5 g of quercetin, not dasatinib. Personal report
Other reports use different amounts and partners. Cypherpunk reports 100 mg D with 2000 mg Q, sometimes 150 mg D. Another log uses 100 mg D with 1000 mg Q, then 1600 mg Q plus 400 mg fisetin. These are separate experiments. Rapamycin.news Personal report
Forms and copied numbers are not interchangeable. Community charts discuss 100 mg D with roughly 1000–1500 mg Q daily for 2–3 days. Fisetin additions or substitutions and quercetin powders versus enhanced-absorption products change the experiment; matching milligrams does not establish equivalence. Community Community

Half-life: drug clearance

The circulated four-hour figure comes from research. LongeCity quotes a paper giving approximately 4 hours for D and 11 hours for Q. Those are research-derived elimination figures repeated in a forum, not community measurements. Half-life means the time for drug concentration to fall by half; it does not time a rejuvenation effect. LongeCity

Onset: when people notice something

Unwanted effects can start within hours. KarlT describes nausea/headache within hours and rigors—strong shaking chills—12–15 hours after one dose. Another poster notices head fullness by evening after morning dosing. Feeling ill is not evidence that senescent cells are being cleared. Personal report
Benefit has no dependable start time. The vitality account describes days after dosing; other reports describe energy/recovery weeks later. Others notice nothing. The 1–2-week 'clearance' narrative borrows study follow-up timing, not measured benefit onset. Rapamycin.news Community LongeCity

Duration: how long changes last

A headache may clear overnight; other symptoms are reported later. Bataille describes a first-night headache gone by morning and little sensation on day two. Basil_Dev reports nausea six days later and fatigue/stomach unease four days after a later pulse. These timings do not show that dasatinib remains active for days. Personal report
The benefit window remains unknown. Accounts emphasize long drug-free weeks and reassessment across months. LongeCity's 11-day claim refers to biopsy findings after a small kidney-disease study, not 11 days of energy or guaranteed protection until the next pulse. Community LongeCity

Cycles: widely different calendars

Two days every other month versus repeated three-day clusters. Todd reports two consecutive days every other month. George reports three consecutive days each week for three weeks, repeating every 4–5 months. Cypherpunk's single-dose quarterly pattern is different again. No healthy-user cadence is validated by these logs. Personal report Rapamycin.news
Weekly, monthly and longer breaks also appear. Community calendars include 11–28-day off periods, monthly 2–3-day blocks, every-other-month use and quarterly clusters. A Reddit commenter describes monthly use for two years without a defined benefit; a proposed 100 mg schedule in the replies is a plan, not an outcome. Community Reddit r/Biohackers

What materially changes the risk

Brief courses still involve a potent prescription drug. Label warnings include low blood-cell counts, bleeding, fluid around the lungs, pulmonary hypertension, rhythm problems and fetal harm; clinical monitoring matters. Oncology frequencies cannot estimate intermittent-user risk. Brief exposure does not establish safety. Official context
Medication interactions can substantially change exposure. CYP3A4 inhibitors or inducers and acid-reducing medicines alter dasatinib levels. Rapamycin stacks complicate assessment. The label separates antacids by at least two hours and avoids PPIs/H2 blockers; that context is not a workaround for self-prescribing. Official context Community
A new mouse warning deserves its actual scope. A March 2026 PNAS paper found myelin damage in young and aged mice given D+Q. It is an animal warning, not proof of human brain damage or an established safe age threshold. Animal context

What formal research adds

Clinical clearance is measured in hours. The Sprycel label gives a mean terminal half-life of 3–5 hours and peak blood concentrations at 0.5–6 hours after oral dosing. Neither establishes benefit onset or duration. Official context
The bone trial used different D and Q day counts. Farr's 60-woman trial used oral D 100 mg/day for two days and Q 250 mg four times daily (1000 mg/day) for three days, every 28 days for five sessions over 20 weeks. Its primary bone-resorption outcome was unchanged; early formation-marker gains faded by week 20. Official context
Mouse doses stay in the animal category. Xu's older-mouse lifespan work used D 5 mg/kg + Q 50 mg/kg by oral gavage, including three-day courses every two weeks. Those amounts and survival findings do not supply human dose conversions or a longevity promise. Animal context

What the community experience adds

Tolerance differs sharply. One three-day user reports no sides at 100 mg; another describes vomiting, neck stiffness, fatigue and swollen hands. Rapamycin.news
Some abandon the experiment. A later Revisit poster stopped because diarrhea was intolerable. Rapamycin.news
Stack stories make attribution difficult. The positive log added taurine and GlyNAC after improvement; rapamycin was present from the start. Stack charts also include metformin, NMN/NR, spermidine, exercise and sleep. D+Q+fisetin and fisetin-only comparisons do not establish synergy or equivalent alternatives. Personal report Community
Preventive expectations can coexist with no noticeable benefit. Bataille describes use as preventive despite no felt benefit. The Reddit monthly-use claim says 'works great' without naming an outcome, while warning about vomiting. Personal confidence and continued use cannot substitute for a defined change or safety evidence. Personal report Reddit r/Biohackers
Supply doubts are practical, but symptoms cannot authenticate tablets. Age Reversal replies compare inconsistent packaging, capsules versus tablets and unassayed products. Community cautions flag counterfeit and amount uncertainty. Visual similarity or a familiar headache cannot establish identity, purity or dose. Age Reversal Forum Community